Inhibrx (INBX)
(Delayed Data from NSDQ)
$34.16 USD
+0.10 (0.29%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $34.11 -0.05 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Inhibrx, Inc. (INBX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$32.67 | $36.00 | $27.00 | -4.08% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Inhibrx, Inc. comes to $32.67. The forecasts range from a low of $27.00 to a high of $36.00. The average price target represents a decline of 4.08% from the last closing price of $34.06.
Analyst Price Targets (3 )
Broker Rating
Inhibrx, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on three recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 2.50 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/23/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Hold |
1/23/2024 | JMP Securities | Reni Benjamin | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 3 |
Average Target Price | $32.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | NA |